Table 3.

Patient distribution by NCCN HR and VHR risk groups and 4 year b-DFS, MFS, CSS and OS

	2014		2014+>2 HR		2015		2015+>2 HR
	HR	VHR	HR	VHR	HR	VHR	HR	VHR
N	166	37	131	72	100	103	65	138
%	82%	18%	64.5%	35.5%	49%	51%	32%	68%
4y bDFS % (95% CI)	89 (82–93)	83 (66–92)	89 (82–93)	84 (73–91)	90 (82–95)	85 (75–91)	92 (80–97)	85 (78–90)
4y MFS % (95% CI)	90 (84–94)	83 (63–93)	92 (84–96)	85 (72–92)	93 (85–97)	85 (75–92)	93 (78–98)	87 (80–92)
4y CSS % (95% CI)	100	92 (70–98)	100	95 (82–99)	100	97 (88–99)	100	98 (91–99)
4y OS % (95% CI)	96 (92–99)	85 (64–94)	98 (93–100)	87 (74–94)	96 (89–99)	92 (83–96)	100	91 (84–96)

HR = High Risk, VHR = Very High Risk, b-DFS = biochemical disease free survival, MFS = metastasis free survival, CSS = cause specific survival, OS = overall survival

NCCN 2014 HR= Stage: T3a, Gleason: 8–10, PSA>20, VHR= T3B, T4

NCCN 2015 HR= Stage: T3a, Gleason: 8–10, PSA>20, T3b-T4, Primary Gl 5, >4 cores with Gl 8–10